Citicoline (CDP-Choline)
Cytidine 5'-diphosphocholine
A choline donor studied for memory, attention, and post-stroke cognition, with genuinely mixed results.
Mixed evidence
🧠Nootropic
Evidence tier
Mixed
Research weight
Citations
13 verified / 13
Classification
Nootropic
❝
What the evidence says. Conflicting results across studies; benefit uncertain.
What is Citicoline (CDP-Choline)?
Citicoline (CDP-Choline) (Cytidine 5'-diphosphocholine) is a nootropic used for may modestly improve episodic memory and attention in healthy older adults and people with age-related cognitive decline (small trials).. NutriDex grades the human evidence as Mixed. Citicoline (CDP-choline) is a naturally occurring nucleotide that serves as an intermediate in the synthesis of phosphatidylcholine, a key brain-cell membrane component, and as a source of choline. Small randomized trials and meta-analyses report modest improvements in memory, attention, and cognitive status in older adults and in people with mild cognitive impairment, Alzheimer's disease, or post-stroke cognitive decline, with pooled effect sizes that are small-to-moderate. However, the underlying studies are frequently small and at high risk of bias favoring the intervention, and benefits for everyday functioning and prevention of dementia are not established. In acute stroke specifically, the evidence is contradictory: the large international ICTUS trial found no benefit over placebo, even though some smaller trials and dose-comparison analyses suggest possible advantages. The compound is generally safe and well tolerated. Overall, citicoline is a plausible but unproven nootropic whose strongest signals come from low-quality data, warranting cautious, honest expectations.
Purported Benefits
✓May modestly improve episodic memory and attention in healthy older adults and people with age-related cognitive decline (small trials).
✓Supplies choline and cytidine, intermediates the body uses to build phosphatidylcholine, a major neuronal membrane phospholipid.
✓Some trials and pooled analyses suggest benefit for cognitive function after ischemic stroke, though the largest stroke trial was negative.
✓Generally well tolerated with a favorable safety profile across trials.
✓May support acetylcholine and dopamine signaling in theory, but this has not translated into reliable clinical benefit for healthy young users.
Evidence by outcome
The same supplement can be well-proven for one use and unproven for another — here is the human evidence graded outcome by outcome.
| Outcome | Evidence | Effect | Studies |
|---|---|---|---|
| Memory & cognition in age-related decline / MCI / dementiaPooled SMDs favor citicoline but reviews rate underlying trials poor-quality with bias favoring intervention; EFSA found no proven memory effect. | Moderate | ↑ benefit · small | 4 |
| Functional recovery after acute ischemic strokeSmaller trials and a 2016 meta-analysis suggest benefit (esp. non-rtPA), but the large ICTUS RCT (n=2298) was negative. | Mixed | ↔ mixed | 3 |
| Episodic memory in healthy older adultsSingle 12-week RCT (n=100) showed greater memory gains vs placebo; not yet replicated at scale. | Preliminary | ↑ benefit · small | 1 |
| Safety / tolerabilityConsistently well tolerated across trials including the large ICTUS stroke RCT. | Moderate | ↑ benefit | 3 |
Dosing & Compounds
Typical Dose
250-500 mg/day orally for cognition; clinical/stroke studies used up to 1,000-2,000 mg/day. Divided doses are common.
Active Compounds
Safety & Cautions
Generally well tolerated; reported side effects are mild and infrequent, including headache, insomnia, gastrointestinal upset (nausea, diarrhea), and occasionally low blood pressure. Long-term safety beyond a few months of supplementation is not well characterized. People taking levodopa should be cautious, as citicoline may enhance levodopa effects. Choline donors can be metabolized to trimethylamine-N-oxide (TMAO); the clinical relevance for cardiovascular risk is unproven but worth noting for those with cardiovascular disease. Avoid or use only under medical supervision in pregnancy and breastfeeding (insufficient data), and in those with serious cardiovascular, hepatic, or neurological conditions. It is a supplement, not a substitute for stroke or dementia treatment; anyone with acute neurological symptoms or a diagnosed cognitive disorder should consult a physician rather than self-treat. Discontinue and seek care if unusual symptoms occur. Educational only — always check with your doctor or pharmacist before combining Citicoline (CDP-Choline) with any medicine.
Key Studies ★ 13 studies
Systematic review / meta-analysis
7 trials, ~1,490 patients
✓ PubMed
A 2023 systematic review and meta-analysis found citicoline improved cognitive status (pooled SMDs 0.56 to 1.57; MMSE +1.55 points) but rated the underlying studies as poor quality with significant risk of bias favoring the intervention.
Network meta-analysis
13 studies, ~5,345 patients
✓ Full text
A 2025 network meta-analysis reported that 500 mg and 2,000 mg citicoline were associated with higher rates of neurological and daily-living improvement and lower mortality in acute ischemic stroke, but could not identify an optimal dose.
Systematic review / meta-analysis
Review
✓ Full text
A 2025 systematic review and meta-analysis comparing choline alphoscerate and citicoline in dementia found both choline donors associated with cognitive benefit but emphasized heterogeneity and limited high-quality evidence.
Meta-analysis
Gareri/Castagna et al. 2023 (Nutrients)
✓ Full text
Systematic review and meta-analysis of 7 studies in MCI, Alzheimer's and post-stroke dementia found citicoline improved cognitive status (pooled SMD ranging 0.56 [95% CI 0.37-0.75] to 1.57 [95% CI 0.77-2.37]), though overall study quality was poor.
Meta-analysis
Sagaro & Amenta 2025 (Front Neurol)
✓ PubMed
Meta-analysis of 3 RCTs (n=358) found choline alphoscerate significantly more effective than citicoline on the SCAG scale (WMD -3.92, 95% CI -7.41 to -0.42), with no significant between-group difference on memory or word fluency tests.
Systematic review
Roberti / Faiq 2023 — Citicoline in glaucoma systematic review
✓ PubMed
Systematic review of clinical studies in glaucoma: citicoline (oral or eyedrops) showed neuroprotective signals (improved PERG amplitude, RNFL, and visual-field mean deviation/slopes) without altering intraocular pressure, though conclusive evidence on long-term progression is still lacking.
Agency / regulator
EFSA NDA Panel 2024
✓ PubMed
EFSA concluded a cause-and-effect relationship has NOT been established between citicoline consumption and improvement, maintenance or reduced loss of memory in middle-aged/elderly adults with age-associated subjective memory impairment.
Meta-analysis
Secades 2016 — Citicoline for acute ischemic stroke meta-analysis
✓ PubMed
Formal meta-analysis of 10 randomized, double-blind, placebo-controlled trials: citicoline significantly increased the rate of functional independence (OR 1.56, 95% CI 1.12-2.16, random effects); effect was larger in non-rtPA patients (OR 1.63, 1.18-2.24) but diluted to limited benefit on top of rtPA.
Cochrane systematic review
14 trials
✓ PubMed
A Cochrane review found some evidence that CDP-choline has a positive short-to-medium-term effect on memory and behaviour in elderly people with chronic cerebral disorders, with good tolerability, but limited by short study duration.
RCT
Cotroneo 2013 (IDEALE study) — Citicoline in mild vascular cognitive impairment
✓ PubMed
Multicenter Italian study, n=349 elderly with mild vascular cognitive impairment: oral citicoline 1000 mg/day kept MMSE stable over 9 months while the control group declined (approx -1.9 points), with good tolerability.
Randomized controlled trial
100 healthy older adults
✓ PubMed
In a 12-week double-blind RCT, citicoline 500 mg/day produced significantly greater improvements in episodic memory and composite memory scores versus placebo (Paired Associate test change 0.15 vs 0.06, P=0.0025).
Randomized controlled trial
2,298 patients
✓ PubMed
The large international ICTUS RCT found that citicoline (1,000 mg twice daily for 6 weeks) was not efficacious for recovery at 90 days in moderate-to-severe acute ischemic stroke, though it confirmed safety.
Review
Bermejo et al. 2023 (Neurosci Insights)
✓ PubMed
Review concluded citicoline shows consistent improvement in cognitive function in patients with mild cognitive impairment, especially of vascular origin.